Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer

Korábbi kezelés

• Refuse chemotherapy or surgery;
• Undergone major surgery within 30 days;

Más betegség

• History of other malignancies (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);
• Accompanied by other serious diseases, including but not limited to: compensatory heart failure (NYHA grade III and IV), unstable angina, poorly controlled arrhythmias, uncontrolled hypertension (SBP>160mmHg or DBP>100mmHg); active infections; unmanageable diabetes mellitus; presence of uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage; severe portal hypertension; gastric outlet obstruction; Respiratory insufficiency;
• Known allergy to prescription or any component of the prescription used in this study;
• With HIV, HPV, or syphilis infection, or active hepatitis (hepatitis B, hepatitis C)

Laborértékek

• Use of EGFR-mab or EGFR-TKI within 30 days;

Egyéb

• Other reasons that are not suitable to participate in this study according to the researcher's judgment

• Age 18-75 years old, gender unlimited;
• Histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC);
• Locally advanced pancreatic cancer, no evidence of distant metastasis as demonstrated by imaging;
• Receive nimotuzumab and NALIRIFOX for voluntary, and patients can tolerate NALIRIFOX by researcher's evaluation;
• No prior tumor systemic therapy.
• Measurable disease according to RECIST criteria v1.1;
• Adequate organ and bone marrow function, defined as follows: hemoglobin≥9.0 g/dL; absolute neutrophil count (ANC)≥1.5×10\^9/L; platelets≥100×10\^9/L; serum total bilirubin (TBIL)≤1.5×ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the upper limit of normal (ULN); serum creatinine≤1.5×ULN or estimated creatinine clearance > 60 mL/min;
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
• Postoperative survival was expected to be ≥3 months;
• Fertile subjects are willing to take contraceptive measures during the study period.
• Good compliance and signed informed consent voluntarily.